TRAF3IP2 and rheumatoid arthritis: For instance, IGU can inhibit IL-6 and IL-8 in RA synovial fibroblast-like cells by interfering with NF-κB [17,18], IL-17-mediated signaling by disrupting Act1 or MIF [19], and B cell differentiation by disrupting the PKC pathway [20].